Ingrid Hedenfalk
Ingrid Hedenfalk
Department of Oncology, Clinical Sciences, Lund University, Sweden
Verified email at - Homepage
Cited by
Cited by
Gene-expression profiles in hereditary breast cancer
I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ...
New England Journal of Medicine 344 (8), 539-548, 2001
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis
M Esteller, MF Fraga, M Guo, J Garcia-Foncillas, I Hedenfalk, AK Godwin, ...
Human molecular genetics 10 (26), 3001-3007, 2001
An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression
A Palazon, PA Tyrakis, D Macias, P Veliça, H Rundqvist, S Fitzpatrick, ...
Cancer cell 32 (5), 669-683. e5, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
F Cardoso, JMS Bartlett, L Slaets, CHM Van Deurzen, ...
Annals of Oncology 29 (2), 405-417, 2018
Molecular classification of familial non-BRCA1/BRCA2 breast cancer
I Hedenfalk, M Ringnér, A Ben-Dor, Z Yakhini, Y Chen, G Chebil, R Ach, ...
Proceedings of the National Academy of Sciences 100 (5), 2532-2537, 2003
Clinical and molecular complexity of breast cancer metastases
S Kimbung, N Loman, I Hedenfalk
Seminars in cancer biology 35, 85-95, 2015
RNA quality in frozen breast cancer samples and the influence on gene expression analysis–a comparison of three evaluation methods using microcapillary electrophoresis traces
C Strand, J Enell, I Hedenfalk, M Fernö
BMC molecular biology 8, 1-9, 2007
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker
I Johansson, C Nilsson, P Berglund, M Lauss, M Ringnér, H Olsson, ...
Breast Cancer Research 14, 1-15, 2012
MYB Oncogene Amplification in Hereditary BRCA1 Breast Cancer
P Kauraniemi, I Hedenfalk, K Persson, DJ Duggan, M Tanner, ...
Cancer research 60 (19), 5323-5328, 2000
Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk
N Orr, A Lemnrau, R Cooke, O Fletcher, K Tomczyk, M Jones, N Johnson, ...
Nature genetics 44 (11), 1182-1184, 2012
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer
K Rennstam, N McMichael, P Berglund, G Honeth, C Hegardt, L Rydén, ...
Breast cancer research and treatment 122, 315-324, 2010
Gene expression in inherited breast cancer
IA Hedenfalk, M Ringnér, JM Trent, A Borg
Academic Press 84, 1-34, 2002
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
NP Tobin, JC Harrell, J Lövrot, SE Brage, MF Stolt, L Carlsson, Z Einbeigi, ...
Annals of oncology 26 (1), 81-88, 2015
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer
I Johansson, C Nilsson, P Berglund, C Strand, G Jönsson, J Staaf, ...
Breast cancer research and treatment 129, 747-760, 2011
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
M Feldt, O Bjarnadottir, S Kimbung, K Jirström, PO Bendahl, S Veerla, ...
Journal of translational medicine 13, 1-11, 2015
Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
S Kimbung, A Kovács, PO Bendahl, P Malmström, M Fernö, T Hatschek, ...
Molecular oncology 8 (1), 119-128, 2014
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer
S Deb, I Johansson, D Byrne, C Nilsson, L Constable, ML Fjällskog, ...
Modern Pathology 27 (9), 1223-1230, 2014
The landscape of candidate driver genes differs between male and female breast cancer
I Johansson, M Ringnér, I Hedenfalk
PloS one 8 (10), e78299, 2013
Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact
C Nilsson, I Johansson, C Ahlin, S Thorstenson, RM Amini, M Holmqvist, ...
Acta Oncologica, 2012
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
S Kimbung, E Biskup, I Johansson, K Aaltonen, A Ottosson-Wadlund, ...
Cancer letters 319 (2), 232-241, 2012
The system can't perform the operation now. Try again later.
Articles 1–20